Novartis AG, of Basel, Switzerland, said its U.S. subsidiary, Novartis Pharmaceuticals Corp. (NPC), finalized a settlement to resolve a civil suit filed by the U.S. Attorney's Office for the Southern District of New York related to interactions with specialty pharmacies for Exjade (deferasirox) and Myfortic (mycophenolic acid).